Physician profile
Ramon A Robles
NPI 1659577039
$38,039.71
in general payments reported to CMS, 2019-2025
13 companies · $37K in 2025
The $37K reported for 2025 was more than what 99% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $152 · 2021: $172 · 2022: $47.28 · 2023: $94.66 · 2024: $532 · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $37K · Food and Beverage: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $36,646.88 |
| Food and Beverage | $740.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $36,646.88 | 2025 | |
| Aroa Biosurgery Incorporated | $374.45 | 2024-2025 | |
| Mentor Worldwide LLC | $304.79 | 2019-2023 | Mentor Memorygel Resterilizable Gel Sizer |
| Merz North America, INC. | $162.77 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $123.66 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $116.90 | 2019 | |
| Abbvie INC. | $108.67 | 2024 | |
| Integra Lifesciences Corporation | $74.99 | 2024 | Integra |
| Polynovo North America LLC | $58.16 | 2024-2025 | Novosorb Btm |
| Galderma Laboratories, L.P. | $38.91 | 2019 | |
| Acera Surgical, INC. | $15.90 | 2024 | Restrata Wound Matrix |
| Smith+Nephew, INC. | $13.63 | 2025 | Renasys Touch, Pico 14 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Robles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.